Risperidone in the treatment of psychotic depression

Goto, Makiko; Yoshimura, Reiji; Kakihara, Shingo; Shinkai, Koji; Yamada, Yasuhisa; Kaji, Kyoko; Ueda, Nobuhisa; Nakamura, Jun

doi:10.1016/j.pnpbp.2006.01.016

Cited by 29 publications

(12 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, recent reports suggest that risperidone is useful for treating refractory depression (Goto et al, 2005;Papakostas et al, 2007). Rapaport et al (2006) investigated the longterm efficacy of risperidone augmentation of SSRI treatment for resistant depression.…”

Section: Introductionmentioning

confidence: 99%

Addition of risperidone to sertraline improves sertraline‐resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline

Yoshimura

Umene-Nakano

Ueda

et al. 2008

Human Psychopharmacology

Self Cite

View full text Add to dashboard Cite

In the present study, we examined the efficacy of risperidone addition on sertraline-resistant depressed patients and the effects of risperidone on the metabolism of sertraline. Ten patients (M/F: 4/6, age: 54 +/- 10 years) met the DSM-IV criteria for major depressive disorder enrolled the study. Hamilton Dating Scale for Depression (HAM-D) scores (mean +/- SD) in all 10 patients significantly decreased from 19 +/- 4 (before risperidone addition) to 11 +/- 3 (4 weeks after risperidone addition). Plasma levels of sertraline and desmethylsertraline did not change after risperidone addition. Serum BDNF levels in responders to risperidone addition were changed from 8.1 +/- 2.7 ng/ml (before risperidone addition) to 11.5 +/- 0.9 ng/ml (4 weeks after risperidone addition); in contrast, those in nonresponders changed from 7.8 +/- 2.2 ng/ml (before risperidone addition) to 7.9 +/- 2.4 ng/ml (4 weeks after risperidone addition). These results suggest that the addition of risperidone to sertraline is effective and well tolerated for sertraline-resistant depressive patients, which is accompanied with the increase in serum BDNF levels in responders to the risperidone addition, and the addition of risperidone to sertraline does not seem to influence sertraline metabolism.

show abstract

Section: Introductionmentioning

confidence: 99%

Addition of risperidone to sertraline improves sertraline‐resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline

Yoshimura

Umene-Nakano

Ueda

et al. 2008

Human Psychopharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

“…These results indicate that one of the mechanisms responsible for the risperidone augmentation of refractory depression is associated with its suppression of the dopaminergic system 12 . In addition, we have reported that risperidone has little effect on paroxetine metabolism 12 . Thus, it seems unlikely in the present case that adding risperidone to paroxetine increased plasma paroxetine levels and that this was responsible for the observed clinical improvement.…”

Section: Discussionmentioning

confidence: 56%

“…One possibility is that paroxetine was effective in treating the depressive symptoms and risperidone was effective in treating the musical hallucinations; another possibility is that the combination of risperidone and paroxetine was effective in treating the core depressive symptoms and that the musical hallucination improved as a result of the relief of the depressive state. Recently, we have reported that risperidone augmentation of treatment with antidepressant drugs or mood stabilizers is effective for non‐vascular psychotic depression with or without hallucinations, 12 and we have also demonstrated that risperidone combined with antidepressant drugs or mood stabilizers significantly decreases plasma levels of homovanillic acid (HVA), a major metabolite of dopamine. These results indicate that one of the mechanisms responsible for the risperidone augmentation of refractory depression is associated with its suppression of the dopaminergic system 12 .…”

Section: Discussionmentioning

confidence: 99%

“…Recently, we have reported that risperidone augmentation of treatment with antidepressant drugs or mood stabilizers is effective for non‐vascular psychotic depression with or without hallucinations, 12 and we have also demonstrated that risperidone combined with antidepressant drugs or mood stabilizers significantly decreases plasma levels of homovanillic acid (HVA), a major metabolite of dopamine. These results indicate that one of the mechanisms responsible for the risperidone augmentation of refractory depression is associated with its suppression of the dopaminergic system 12 . In addition, we have reported that risperidone has little effect on paroxetine metabolism 12 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A case of vascular depression associated with musical hallucinations successfully treated with paroxetine and a low dose of risperidone

et al. 2008

Self Cite

View full text Add to dashboard Cite

Herein, we report a case of an 83-year-old man with vascular depression associated with musical hallucinations. Brain magnetic resonance imaging disclosed diffuse brain atrophy with multiple higher-density zones in the white matter and basal ganglia. Single photon emission computed tomography images showed areas of hypoperfusion in the bilateral temporal lobe and basal ganglia. Combination treatment with paroxetine and a low dose of risperidone rapidly improved both the depressive symptoms and musical hallucinations.

show abstract

“…Retrospective chart reviews [50,51] and case reports [52] and a small open-label study [53] suggest an effectiveness for risperidone in treating MDDp. Effectiveness for quetiapine has been reported in case reports [54,55] a retrospective chart review [56] as well as a recent open-label study [57].…”

Section: Discussionmentioning

confidence: 99%

Olanzapine in the treatment of depression with psychotic features: A prospective open-label study

Adli

Wiethoff

Baethge

et al. 2008

International Journal of Psychiatry in Clinical Practice

View full text Add to dashboard Cite

Objective. Depression with psychotic features is a severe subtype of major depression associated with the presence of delusions, hallucinations and specific neurobiological features. Despite clinical consensus and guideline recommendations, data comparing the efficacy of combining antipsychotics with antidepressants compared to antidepressants alone remain inconclusive. The aim of the study was to investigate effectiveness and tolerability of the atypical antipsychotic olanzapine in acute depression with psychotic features. Methods. Seventeen inpatients with major depressive disorder with psychosis (MDDp) were treated with a combination of an antidepressant and olanzapine for 6 weeks in a prospective open-label study. Depressive and psychotic symptoms, extrapyramidal and general side effects were assessed every 2 weeks. Sixteen patients were eligible for final analysis. Results. The Brief Psychiatric Rating Scale (BPRS) showed a 30% symptom reduction after week 2, a 45% symptom reduction after week 4 and no considerable improvement thereafter. Depressive symptoms (Bech-Rafaelsen Melancholia Scale, BRMS) receded by 37% after week 2 and 50% after week 4. No extrapyramidal side effects occurred. Conclusion. Olanzapine is effective and tolerable in combination with an antidepressant in an MDDp inpatient sample. The results concur with data supporting good efficacy in negative and depressive symptoms of patients with schizophrenic and schizoaffective diseases.

show abstract

Risperidone in the treatment of psychotic depression

Cited by 29 publications

References 38 publications

Addition of risperidone to sertraline improves sertraline‐resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline

Addition of risperidone to sertraline improves sertraline‐resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline

A case of vascular depression associated with musical hallucinations successfully treated with paroxetine and a low dose of risperidone

Olanzapine in the treatment of depression with psychotic features: A prospective open-label study

Contact Info

Product

Resources

About